Nuclear Regulatory Commission March 18, 2008 – Federal Register Recent Federal Regulation Documents
Results 1 - 6 of 6
Advisory Committee on the Medical Uses of Isotopes: Meeting Notice
NRC will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) April 28-29, 2008. A sample of agenda items to be discussed during the public session includes: (1) ACMUI comments on the National Academies of Sciences report (https:// www.nap.edu/catalog.php?recordid=11976); (2) ACMUI subcommittee recommendations on regulating the Leksell Gamma-Knife[reg] Perfexion\TM\; (3) potential revisions to the Abnormal Occurrence criteria; (4) subcommittee report on medical events and analysis of causes; (5) emerging technology; (6) yttrium 90 microsphere guidance; (7) status of active petitions for rulemaking; (8) NARM transition plan update; and (9) status of specialty board applications for NRC recognition. A copy of the agenda will be available at https:// www.nrc.gov/reading-rm/doc-collections/acmui/agenda or by e-mailing Ms. Ashley M. Tull at the contact information below. Purpose: Discuss issues related to 10 CFR Part 35 Medical Use of Byproduct Material. Date and Time for Closed Sessions: April 28, 2008 from 3:30 p.m. to 5:30 p.m. This session will be closed so that NRC staff and ACMUI can prepare for the Commission meeting. Date and Time for Open Sessions: April 28, 2008, from 8 a.m. to 3:30 p.m. and April 29, 2008, from 8 a.m. to 3 p.m. Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two White Flint North Building, Room T2-B3, 11545 Rockville Pike, Rockville, Maryland 20852. Public Participation: Any member of the public who wishes to participate in the meeting should contact Ms. Tull using the information below. Contact Information: Ashley M. Tull, e-mail: amt1@nrc.gov, telephone: (301) 415-5294 or (918) 488-0552. Conduct of the Meeting
Expanded Definition of Byproduct Material; Notification of Impending Waiver Termination
Section 651(e) of the Energy Policy Act of 2005 (EPAct) authorized the U.S. Nuclear Regulatory Commission (Commission or NRC) to issue a time-limited waiver (70 FR 51581; August 31, 2005) to allow continued use and possession of naturally-occurring and accelerator- produced radioactive materials (NARM) while the Commission developed a regulatory framework for regulation of the new byproduct material. The Commission has begun terminating the time-limited waiver in phases in accordance to the provisions of the ``Plan for the Transition of Regulatory Authority Resulting from the Expanded Definition of Byproduct Material'' (transition plan) issued by the Commission on October 19, 2007 (72 FR 59157). The first phase of waiver terminations occurred on November 30, 2007. This document provides advance notification that on September 30, 2008, the Commission will terminate the time-limited waivers for the following non-Agreement States and remaining U.S. Territories that have been included in Phase 2. Guam, Idaho, Missouri, South Dakota, Vermont, West Virginia, and all territories and possessions of the U.S. that were not identified as part of the first phase of waiver terminations. As provided in the transition plan, users of NARM in non-Agreement States and U.S. Territories will be required to (1) apply for license amendments for the new byproduct material within 6 months from the date the waiver is terminated, if they hold an NRC specific byproduct materials license; or (2) submit a license application for the new byproduct material within 12 months from the date the waiver is terminated for their State or territory.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
